Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
JAMA Dermatol ; 160(2): 237-238, 2024 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-37950917

RESUMO

This case report describes a 14-year-old girl with juvenile dermatomyositis who presented with a 6-year history of a pruritic, photosensitive eruption involving her face, neck, trunk, and extremities and was successfully treated with anifrolumab.


Assuntos
Dermatomiosite , Humanos , Dermatomiosite/tratamento farmacológico , Pele , Anticorpos Monoclonais Humanizados/uso terapêutico , Administração Cutânea
4.
Transplant Proc ; 55(9): 2079-2084, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37838527

RESUMO

BACKGROUND: Oral nicotinamide (NAM) has shown promise in preventing actinic keratoses (AKs) in trials based outside of the United States. We assessed the efficacy of oral NAM supplementation in kidney transplant recipients with a history of keratinocyte carcinoma. MATERIAL AND METHODS: Patients enrolled in a 2-week run-in phase, during which NAM 1000 mg was taken twice daily. After a washout period, patients who tolerated the run-in phase were randomized to NAM 500 mg twice daily or placebo. At baseline, 4, 8, and 12 months, dermatologists conducted full-body skin exams to document area-specific AKs. Routine lab work was collected to ensure the stability of renal allograft function. RESULTS: The dosage was reduced from 1000 to 500 mg due to gastrointestinal symptoms in the run-in phase. Patients were randomized to NAM (n = 10) or placebo (n = 11). At 12 months, mean AK count was 30.8 (95% CI -11.7-73.4) for NAM and 26.6 (95% CI 10.8-42.5) for placebo. The difference in percent AK count change at 12 months compared with baseline was 259.8% (95% CI -385.9 to 905.5) for NAM and 72.4% (95% CI -118.6 to 263.5) for placebo. The between-group difference in percent AK change was not significant (P = .38). There was no attrition in the placebo group and 40% attrition in the NAM arm. DISCUSSION: Nicotinamide did not decrease AK development among kidney transplant recipients. Limitations include drug tolerability, small sample size, and single-center trial nature.


Assuntos
Ceratose Actínica , Transplante de Rim , Humanos , Ceratose Actínica/diagnóstico , Ceratose Actínica/tratamento farmacológico , Ceratose Actínica/patologia , Niacinamida/efeitos adversos , Transplante de Rim/efeitos adversos , Resultado do Tratamento , Pele/patologia , Método Duplo-Cego
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...